Opyt klinicheskogo primeneniya preparata Nayz v kompleksnoy terapii patsientov s bolyami v kolennom sustave


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

From 2008 to 2011, 244 patients (68 % - women) with pain in the knee joint were treated in the Department of Treatment of Pain Syndromes (DTPS). The average age of the patients was 67,0 ± 16,3 years. The intensity of pain ranged from 4 to 10 points according to the Visual Analogue Scale (VAS), duration of pain ranged from 2 weeks to 6 months. After the examination, the patients were divided into two groups: main group (A) - with high intensity of pain, and control group (B) - with moderate pain. All patients have received a common pathogenetical therapy with COX (cyclooxygenase)-2 selective nonsteroidal anti-inflammatory drugs, central muscle relaxants, and chondroprotectors. In patients with high intensity of pain, blockades of knee joints using small doses of local anesthetics and corticosteroids in addition to the standard drug therapy were performed. Drugs of choice for standard medical therapy were nimesulide, tizanidine, and glucosamine + chondroitin sulfate. Blockades were performed using betamethasone with a local anesthetic. Outcomes were evaluated at 7, 14 and 30 days. The gait performance, joint range of motions, VAS score, and results of psychological testing according to Knee Injury and Osteoarthritis Outcome Score were analyzed. Comparison of the results of treatment in the two groups revealed that long-term use of the Nise (nimesulide) has not only fast anti-inflammatory, decongestant and analgesic effects, but also is well tolerated by elderly patients.

Full Text

Restricted Access

References

  1. Балабанова Р.М. Нимесулид -противовоспалительный препарат с селективним ингибированием ЦОГ-2 // РМЖ 2001. № 9. С. 291-92.
  2. Гнездилов А.В., Овечкин А.М., Иванова Л.Г. и др. Современнье принципи лечения хронической боли в комплексной реабилитации пациентов с патологией опорно-двигательного аппарата // Мед.-соц. зксперт. и реабил. 2000. № 2. С. 8-12.
  3. Гребенева Л.С, Насонова С.В., Цветкова Л.И. Побочнье зффекть лечения нестероидньми противовоспалительньми препаратами и пути их коррекции// Клин. мед. 1997. № 5. С. 42-5.
  4. Загорулько О.И. Клинические, методические и организационнье аспекть терапии боли. Дисс. докт. мед. наук. М., 2002.
  5. Марусенко И.М, Везикова Н.Н., Игнатьев В.К. Разумньй вьбор НПВС при сочетанной патологии: заболеваниях суставов и гипертонической болезни // Лечащий врач 2004. № 2. С. 76-7.
  6. Медведева Л.А. НПВП и дополнительнье возможности в терапии цервикокраниальной боли / Врач 2011. № 4. С. 73-79.
  7. Гнездилов А.В, Иванов А.М., Овечкин А.М. и др. Методь лечения болевого синдрома у больньх ортопедического профиля: Методические рекомендации. М.,1999.
  8. Насонов Е. Л. Перспективы применения нового нестероидного противовоспалительного препарата нимесулид // Клин. фармакол. и терапия 1999. № 8. С. 65-9.
  9. Насонов Е.Л. Современное учение о селективных ингибиторах ЦОГ-2: новье аспекть применения мелоксикама (мовалиса) // Научно-практич. ревматол. 2001. № 1. С. 58-62.
  10. Насонова В.А., Фоломеева О.М. Медико-социальное значение XIII класса болезней для населения России // Научно-практическая ревматология 2001. № 1. С. 7-11.
  11. Насонов Е.Л., Цветкова Е.С., Тов Н.Л. Селективнье ингибиторы циклооксигеназь-2: новье перспективы лечения заболеваний человека // Тер. архив 1998. № 5. С. 8-14.
  12. Николаев А.Н. Нестероиднье противовоспалительнье препарать: зффективность и безопасность//РМЖ2001. № 15. С. 664,666.
  13. Arfag A, Davies P. Osteoarthritis. Current drug treatment regimens. Drugs 1991;41:193-201.
  14. Bennet A, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000;1:277-86.
  15. Bernareggi A. Clinical pharmacokinetics of nime-sulide. ClinicalPharmacokinet 1998;35:247-74.
  16. Bessone F, Colombato L, Fassio E, et al. The Spectrum of Nimesulide-Induced-Hepatotoxicity. An Overview: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu) 2010;9(4):355-65( 11).
  17. Bianchi M, Ferrario P, Balzarini P, Broggini M. Plasma and synovial fluid concentration of nimesu-lidi and its main metabolite after single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006;34(4):348-54.
  18. Fioravanti A, Storri L, Di Martino S, et al. A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis. Clin Ther 2002;24(4):504-19.
  19. Merlani G, Fox M, Oehen H-P, Cathomas G ,et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001 ;57(4):321-26.
  20. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003;327:18.
  21. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti inflammatory drug therapy. JAMA 1994;272: 781-86.
  22. Jonson AG, Nguyen TV, Day RO. Do nonsteroidal anti inflammatory drugs affect blood pressure? A meta analysis. Ann. Intern. Med 1994:121:289300.
  23. Mattia C, Ciarcia S, Muhindo A, Coluzzi F. Nimesulide: 25 years later. Minerva Med 2010; 01(4):285-93.
  24. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
  25. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulidi ( 100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005;24(2): 128-33.
  26. Rabasseda X. Safety profile of nimesulide: ten years of clinical experience. Drugs Today 1997; 33(Suppl. 1):1-11.
  27. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;(2):CD002946.
  28. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX 2 therapy. J Rheumatol 2002;29:467-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies